Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 1/20 | 0.40 |
| ▸ | SMO | Q99835 | 1/20 | 0.39 |
| ▸ | RORC | P51449 | 1/20 | 0.36 |
| ▸ | KDM2B | Q8NHM5 | 1/20 | 0.36 |
| ▸ | KDM4C | Q9H3R0 | 2/20 | 0.36 |
| ▸ | KDM5A | P29375 | 1/20 | 0.36 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | HTR2C | P28335 | 1/20 | 0.35 |
| ▸ | PARG | Q86W56 | 1/20 | 0.35 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.35 |
| ▸ | ATM | Q13315 | 1/20 | 0.35 |
| ▸ | GRM5 | P41594 | 3/20 | 0.35 |
| ▸ | PLK1 | P53350 | 1/20 | 0.35 |
| ▸ | HTR3A | P46098 | 2/20 | 0.34 |
| ▸ | CNR1 | P21554 | 1/20 | 0.34 |
| ▸ | IDO1 | P14902 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24547743 | 0.91 | HSD11B1 (0.38) | HSD11B1SMORORCKDM2BALDH1A1 | |
| SCHEMBL24547660 | 0.83 | ELANE (0.45) | ALDH1A1 | |
| SCHEMBL24547757 | 0.83 | ELANE (0.45) | ALDH1A1 | |
| SCHEMBL24547758 | 0.82 | ELANE (0.46) | ALDH1A1 | |
| SCHEMBL24547762 | 0.72 | HSD17B10 (0.41) | ALDH1A1CNR1 | |
| SCHEMBL24547633 | 0.70 | RIPK1 (0.38) | ALDH1A1HTR3ACNR1 | |
| SCHEMBL15509260 | 0.68 | METAP2 (0.50) | HSD11B1ALDH1A1 | |
| SCHEMBL24547678 | 0.68 | ELANE (0.42) | ALDH1A1 | |
| SCHEMBL24547763 | 0.68 | TFPI2 (0.42) | HSD11B1ALDH1A1 | |
| SCHEMBL24547680 | 0.67 | ELANE (0.41) | ALDH1A1CNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240067654-A1 | OXYTOCIN RECEPTOR MODULATORS | Kinoxis Therapeutics Pty Ltd (AU) | 2024-02-29 | — | — | US | disclosed |
| US-20240067654-A1 | OXYTOCIN RECEPTOR MODULATORS | Kinoxis Therapeutics Pty Ltd (AU) | 2024-02-29 | — | — | US | disclosed |
| WO-2022126179-A1 | OXYTOCIN RECEPTOR MODULATORS | THE UNIVERSITY OF SYDNEY (AU) | 2022-06-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240067654-A1 | OXYTOCIN RECEPTOR MODULATORS | OXTR, AVPR1B, AVPR1A | HSD11B1 313/4885SMO 4223/4885RORC 1601/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.